Leone D. Patterson - Apr 10, 2025 Form 4 Insider Report for Kalaris Therapeutics, Inc. (KLRS)

Role
Director
Signature
/s/ Andrew Oxtoby, Attorney-in-Fact
Stock symbol
KLRS
Transactions as of
Apr 10, 2025
Transactions value $
$0
Form type
4
Date filed
4/11/2025, 04:48 PM
Previous filing
Apr 4, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KLRS Stock Option (Right to Buy) Award $0 +18K $0.00 18K Apr 10, 2025 Common Stock 18K $7.31 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments from April 3, 2025 through April 3, 2028, subject to continuous service.